WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

6 February 2018

Transparency Information ( ENDU )

31 January 2018

Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 ( ENDU )

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
42.75 USD
Change (%):
0.92 (2.20%)
BRU
1.74 EUR
Change (%):
0.03 (1.64%)


ABOUT US

CORPORATE VIDEO

CORPORATE PRESENTATION


FACT SHEET